This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Joint (JYNT), Regeneron (REGN) and Collegium Pharmaceutical (COLL)

Tipranks - Tipranks - Sat May 9, 9:32AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Joint (JYNT), Regeneron (REGN) and Collegium Pharmaceutical (COLL).

Claim 55% Off TipRanks

Joint (JYNT)

In a report released today, Jeremy Hamblin from Craig-Hallum reiterated a Hold rating on Joint, with a price target of $9.00. The company’s shares closed last Friday at $8.87.

According to TipRanks.com, Hamblin is a 4-star analyst with an average return of 8.3% and a 49.9% success rate. Hamblin covers the NA sector, focusing on stocks such as Lucky Strike Entertainment, Savers Value Village Inc., and Red Robin Gourmet. ;'>

The word on The Street in general, suggests a Hold analyst consensus rating for Joint with a $9.64 average price target, a 6.2% upside from current levels. In a report issued on April 25, TipRanks – xAI also reiterated a Hold rating on the stock with a $9.00 price target.

See today’s best-performing stocks on TipRanks >>

Regeneron (REGN)

Truist Financial analyst Gregory Renza maintained a Buy rating on Regeneron today. The company’s shares closed last Friday at $711.94, close to its 52-week low of $629.02.

According to TipRanks.com, Renza is a 5-star analyst with an average return of 17.9% and a 47.5% success rate. Renza covers the Healthcare sector, focusing on stocks such as Ascentage Pharma Group International Unsponsored ADR, Perspective Therapeutics, and Abivax SA Sponsored ADR. ;'>

Regeneron has an analyst consensus of Strong Buy, with a price target consensus of $886.35, representing a 25.0% upside. In a report issued on April 23, Cantor Fitzgerald also maintained a Buy rating on the stock with a $800.00 price target.

Collegium Pharmaceutical (COLL)

Truist Financial analyst Les Sulewski reiterated a Buy rating on Collegium Pharmaceutical today. The company’s shares closed last Friday at $38.08.

According to TipRanks.com, Sulewski is a 4-star analyst with an average return of 9.2% and a 52.8% success rate. Sulewski covers the Healthcare sector, focusing on stocks such as Bausch Health Companies, Pacira Pharmaceuticals, and Amneal Pharmaceuticals. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Collegium Pharmaceutical with a $53.40 average price target, which is a 34.7% upside from current levels. In a report released yesterday, TipRanks – Google also upgraded the stock to Buy with a $41.00 price target.

Read More on JYNT:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).